Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

BIOMARIN PHARMACEUTICAL INC.

(BMRN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

BioMarin Pharmaceutical : Morgan Stanley Adjusts Price Target on BioMarin Pharmaceutical to $82 From $85, Maintains Equal-Weight Rating

04/19/2021 | 12:53pm EDT


© MT Newswires 2021
All news about BIOMARIN PHARMACEUTICAL INC.
07/22BIOMARIN PHARMACEUTICAL : Announces Oral Presentation at International Society
AQ
07/21BIOMARIN PHARMACEUTICAL : Pharma's Gene Therapy Candidate Shows Bleed Control Ov..
MT
07/21BIOMARIN PHARMACEUTICAL : Announces Oral Presentation at International Society o..
PR
07/20BIOMARIN PHARMACEUTICAL : Announces Oral Presentation of Positive One-Year Resul..
AQ
07/19BIOMARIN PHARMACEUTICAL : Announces Oral Presentation of Positive One-Year Resul..
PR
07/19BioMarin Announces Oral Presentation of Positive One-Year Results from Phase ..
CI
07/15BIOMARIN PHARMACEUTICAL : European Regulator Accepts BioMarin's Marketing Applic..
MT
07/15BIOMARIN PHARMACEUTICAL : European Medicines Agency Validates BioMarin's Marketi..
PR
07/15European Medicines Agency Validates Biomarin's Marketing Authorization Applic..
CI
07/14BIOMARIN TO HOST SECOND QUARTER 2021 : 30pm ET
PR
More news
Financials (USD)
Sales 2021 1 822 M - -
Net income 2021 -99,0 M - -
Net cash 2021 183 M - -
P/E ratio 2021 -146x
Yield 2021 -
Capitalization 14 078 M 14 078 M -
EV / Sales 2021 7,63x
EV / Sales 2022 6,20x
Nbr of Employees 3 059
Free-Float 99,4%
Chart BIOMARIN PHARMACEUTICAL INC.
Duration : Period :
BioMarin Pharmaceutical Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIOMARIN PHARMACEUTICAL INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Last Close Price 77,04 $
Average target price 107,86 $
Spread / Average Target 40,0%
EPS Revisions
Managers and Directors
Jean-Jacques Bienaimé Chairman & Chief Executive Officer
Brian R. Mueller Chief Financial Officer & Executive Vice President
Henry J. Fuchs President-Worldwide Research & Development
Eduardo E. Von Pervieux Chief Information Officer
Geoffrey M. Nichol Chief Medical Officer & Senior Vice President
Sector and Competitors